As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer ...

TOKYO & BASKING RIDGE, N.J., June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) plus pertuzumab demonstrated a ...